SCHEMBL18924687

SCHEMBL18924687

O=CN[C@H]1CCOC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18924672 1.00
SCHEMBL772329 1.00
SCHEMBL18724693 0.86
SCHEMBL1911382 0.86
SCHEMBL18724761 0.86
SCHEMBL361400 0.85
SCHEMBL16609932 0.79
SCHEMBL27936411 0.77
SCHEMBL12802126 0.76 MAPK1 (0.33)
SCHEMBL10866589 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115803322-B SARS-COV-2 inhibitors with covalent modifications for treatment of coronavirus infection 英矽智能科技知识产权有限公司 2025-05-13 CN disclosed
US-20230174488-A1 SARS-COV-2 INHIBITORS HAVING COVALENT MODIFICATIONS FOR TREATING CORONAVIRUS INFECTIONS INSILICO MEDICINE IP LIMITED (HK) 2023-06-08 US disclosed
US-20230174488-A1 SARS-COV-2 INHIBITORS HAVING COVALENT MODIFICATIONS FOR TREATING CORONAVIRUS INFECTIONS INSILICO MEDICINE IP LIMITED (HK) 2023-06-08 US disclosed
CN-115803322-A SARS-COV-2 inhibitors with covalent modification for the treatment of coronavirus infection 英矽智能科技知识产权有限公司 2023-03-14 CN disclosed
EP-4143176-A1 SARS-COV-2 INHIBITORS HAVING COVALENT MODIFICATIONS FOR TREATING CORONAVIRUS INFECTIONS Insilico Medicine IP Limited (HK) 2023-03-08 EP disclosed
US-9670166-B2 Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2017-06-06 US disclosed